These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 24947095)

  • 1. Phase 1 dose escalation study of rigosertib by 2-, 4-, or 8-hour infusion twice-weekly in patients with advanced cancer.
    Advani SH; Achrekar SD; Doval DC; Raghunadharao D; Wilhelm FE; Acharya M
    Indian J Cancer; 2014; 51(1):40-4. PubMed ID: 24947095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.
    Bowles DW; Diamond JR; Lam ET; Weekes CD; Astling DP; Anderson RT; Leong S; Gore L; Varella-Garcia M; Vogler BW; Keysar SB; Freas E; Aisner DL; Ren C; Tan AC; Wilhelm F; Maniar M; Eckhardt SG; Messersmith WA; Jimeno A
    Clin Cancer Res; 2014 Mar; 20(6):1656-65. PubMed ID: 24493827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
    Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
    Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
    Ma WW; Messersmith WA; Dy GK; Weekes CD; Whitworth A; Ren C; Maniar M; Wilhelm F; Eckhardt SG; Adjei AA; Jimeno A
    Clin Cancer Res; 2012 Apr; 18(7):2048-55. PubMed ID: 22338014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.
    Bendell JC; Patel MR; Infante JR; Kurkjian CD; Jones SF; Pant S; Burris HA; Moreno O; Esquibel V; Levin W; Moore KN
    Cancer; 2015 Apr; 121(7):1056-63. PubMed ID: 25411085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
    Navada SC; Fruchtman SM; Odchimar-Reissig R; Demakos EP; Petrone ME; Zbyszewski PS; Holland JF; Silverman LR
    Leuk Res; 2018 Jan; 64():10-16. PubMed ID: 29144985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.
    Schöffski P; Awada A; Dumez H; Gil T; Bartholomeus S; Wolter P; Taton M; Fritsch H; Glomb P; Munzert G
    Eur J Cancer; 2012 Jan; 48(2):179-86. PubMed ID: 22119200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.
    Komrokji RS; Raza A; Lancet JE; Ren C; Taft D; Maniar M; Wilhelm F; List AF
    Br J Haematol; 2013 Aug; 162(4):517-24. PubMed ID: 23789936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
    Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
    J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.
    Plummer R; Vidal L; Griffin M; Lesley M; de Bono J; Coulthard S; Sludden J; Siu LL; Chen EX; Oza AM; Reid GK; McLeod AR; Besterman JM; Lee C; Judson I; Calvert H; Boddy AV
    Clin Cancer Res; 2009 May; 15(9):3177-83. PubMed ID: 19383817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
    Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
    Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
    Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of intestinal permeability of rigosertib (ON 01910.Na, Estybon): correlation with systemic exposure.
    White MP; Babayeva M; Taft DR; Maniar M
    J Pharm Pharmacol; 2013 Jul; 65(7):960-9. PubMed ID: 23738723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.
    Demetri GD; Lo Russo P; MacPherson IR; Wang D; Morgan JA; Brunton VG; Paliwal P; Agrawal S; Voi M; Evans TR
    Clin Cancer Res; 2009 Oct; 15(19):6232-40. PubMed ID: 19789325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.
    Mross K; Frost A; Steinbild S; Hedbom S; Rentschler J; Kaiser R; Rouyrre N; Trommeshauser D; Hoesl CE; Munzert G
    J Clin Oncol; 2008 Dec; 26(34):5511-7. PubMed ID: 18955456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
    Awada A; Piccart MJ; Jones SF; Peck RA; Gil T; Lebwohl D; Wu CY; Burris HA
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):417-25. PubMed ID: 18446338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
    Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.
    Hofheinz RD; Al-Batran SE; Hochhaus A; Jäger E; Reichardt VL; Fritsch H; Trommeshauser D; Munzert G
    Clin Cancer Res; 2010 Sep; 16(18):4666-74. PubMed ID: 20682708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.